Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin...

Area of Science:

• Cardiovascular Health
• Metabolic Disorders
• Endocrinology

Background:

• Previous research suggests intraperitoneal (IP) insulin delivery may influence reverse cholesterol transport (RCT).
• RCT is crucial for managing cholesterol levels and cardiovascular health.

Purpose of the Study:

• To investigate the effects of IP insulin delivery on key parameters of RCT.
• To determine if observed changes are linked to glucose control or a direct effect of IP insulin.

Main Methods:

• RCT studies were conducted in 10 C-peptide-negative type 1 diabetic patients randomized into experimental (A) and control (B) groups.
• Serum-mediated cholesterol efflux from fibroblasts and cholesteryl ester transport protein (CETP) activity were measured before and after 3-6 months of IP insulin use.
• Key metabolic markers including glucose control, LDL, HDL, apoprotein B, and apoprotein A-I were monitored.

Main Results:

• Cholesterol efflux from fibroblasts significantly increased by 9.5% in the IP insulin group (Group A) after 3 months (P < .05).
• CETP activity increased by 25.3% in Group A after 3 months of IP insulin (P < .05).
• No significant changes in glucose control or lipid profiles were observed in either group.

Conclusions:

• Long-term intraperitoneal insulin delivery may enhance cholesterol efflux and CETP activity in type 1 diabetic patients.
• These improvements in reverse cholesterol transport appear to be a direct effect of IP insulin, independent of glycemic control.
• IP insulin therapy may offer a novel therapeutic strategy for improving cardiovascular risk factors in diabetes.